NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.87 +0.17 (+10.00 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$1.70
Today's Range$1.74 - $1.88
52-Week Range$1.00 - $2.92
Volume403,877 shs
Average Volume238,021 shs
Market Capitalization$106.45 million
P/E Ratio-9.35
Dividend YieldN/A
Beta2.17
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.15 million
Book Value$0.92 per share

Profitability

Net Income$-11,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$106.45 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) released its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. The biotechnology company earned $0.15 million during the quarter, compared to the consensus estimate of $0.05 million. View Infinity Pharmaceuticals' Earnings History.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Infinity Pharmaceuticals.

What price target have analysts set for INFI?

5 Wall Street analysts have issued twelve-month price objectives for Infinity Pharmaceuticals' stock. Their predictions range from $3.00 to $4.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.

What is the consensus analysts' recommendation for Infinity Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Infinity Pharmaceuticals.

Has Infinity Pharmaceuticals been receiving favorable news coverage?

Media stories about INFI stock have trended very negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest in March. As of March 15th, there was short interest totalling 506,792 shares, a decline of 33.8% from the February 28th total of 765,331 shares. Based on an average daily trading volume, of 402,277 shares, the short-interest ratio is presently 1.3 days. Approximately 0.9% of the company's stock are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Rex Energy (REXX), Continental Resources (CLR), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), Novavax (NVAX), Aerie Pharmaceuticals (AERI), Celgene (CELG), Bausch Health Companies (BHC), Johnson & Johnson (JNJ) and AVEO Pharmaceuticals (AVEO).

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
  • Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
  • Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
  • Ms. Melissa Hackel, VP of Fin.

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.94%), Dimensional Fund Advisors LP (1.94%), Acadian Asset Management LLC (0.85%), Fosun International Ltd (0.67%), Two Sigma Investments LP (0.16%) and Clear Harbor Asset Management LLC (0.13%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Which institutional investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Clear Harbor Asset Management LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Infinity Pharmaceuticals company stock in the last year include Adelene Q Perkins and Jeffery Kutok. View Insider Buying and Selling for Infinity Pharmaceuticals.

Which institutional investors are buying Infinity Pharmaceuticals stock?

INFI stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Alambic Investment Management L.P., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Two Sigma Securities LLC, Bank of New York Mellon Corp, Virtu Financial LLC and Two Sigma Investments LP. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $1.87.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $106.45 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is http://www.infi.com.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel